Clinical Trial Update: RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A two-stage Phase 1/2 trial evaluating RP-3500 in combination with Olaparib for DNA damage repair pathway-deficient relapsed/refractory chronic lymphocytic leuk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Olaparib (Olaparib)
• RP-3500

Snippet

Sponsor: University of Utah | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-06-03